|
English
|
正體中文
|
简体中文
|
总笔数 :0
|
|
造访人次 :
52805965
在线人数 :
574
教育部委托研究计画 计画执行:国立台湾大学图书馆
|
|
|
"yarchoan"的相关文件
显示项目 1-3 / 3 (共1页)
1
每页显示[10|25|50]项目
| 國立成功大學 |
2024-11 |
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
|
D'Alessio;Antonio;Stefanini;Bernardo;Blanter;Julia;Adegbite;Benjamin;Crowley;Fionnuala;Yip;Vincent;Slater;Sarah;Fulgenzi;Maria, Claudia Angela;Celsa;Ciro;Manfredi;Francesca, Giulia;Pai;Madhava;Goldin;Robert;Ward;Stephen, C.;Fiel;Isabel, Maria;Shu;Daniel, H.;Su;Yung-Yeh;Cortellini;Alessio;Baretti;Marina;Anders;Robert;Yarchoan;Mark;Hsu;Chiun;Marron;Thomas, U.;Pinato;David, J. |
| 國立成功大學 |
2024-01-20 |
Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.
|
Rimassa;Lorenza;Li;Daneng;Ikeda;Masafumi;Yarchoan;Mark;Ryoo;Baek-Yeol;Kossler;Thibaud;Lim;Ho-Yeong;Kwiatkowski;Mariusz;Chang;Ting-Tsung;Kim;Hyun, Jee;Casadei-Gardini;Andrea;Kudo;Masatoshi;Ren;Zhenggang;Calvo;Varela, Maria;Llovet;Josep, M.;Zhang;Yayan;Hatogai;Ken;Siegel;Abby, B.;Cheng;Ann-Lii |
| 國立成功大學 |
2024-01-20 |
Qualification of major pathological response as a surrogate endpoint for relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.
|
D'Alessio;Antonio;Stefanini;Bernardo;Blanter;Julia;Adegbite;Benjamin;Fulgenzi;Claudia, A. M.;Celsa;Ciro;Manfredi;Giulia, F.;Pai;Madhava;Goldin;Robert, D.;Shu;Daniel;Su;Yung-Yeh;Baretti;Marina;Anders;Robert, A.;Yarchoan;Mark;Hsu;Chiun;Marron;Urban, Thomas;Pinato;James, David |
显示项目 1-3 / 3 (共1页)
1
每页显示[10|25|50]项目
|
